Related Experiment Videos
[Efficacy and safety of acarbose treatment of NIDDM]
1Dept. of Medicine C, Wolfson Medical Center, Holon.
Insights
Acarbose effectively lowered blood sugar in patients with non-insulin-dependent diabetes mellitus (NIDDM). The treatment demonstrated safety and tolerability, though glucose levels rose after discontinuation.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Non-insulin-dependent diabetes mellitus (NIDDM) poses a significant global health challenge.
- Effective glycemic control is crucial for preventing long-term diabetic complications.
Purpose of the Study:
- To evaluate the efficacy and safety of acarbose in treating NIDDM patients.
- To assess the impact of acarbose on glycemic control markers.
Main Methods:
- An uncontrolled, multicenter study involving 169 NIDDM patients across 12 Israeli medical centers.
- Acarbose administration for 19 weeks, followed by a 12-week follow-up period.
- Monitoring of HbA1c and postprandial serum glucose levels.
Main Results:
- Significant reduction in HbA1c from 8.5% to 7.5% (p < 0.001) during acarbose treatment.
- Marked decrease in postprandial serum glucose from 283.6 mg/dl to 248.5 mg/dl (p < 0.01).
- Post-treatment follow-up showed an increase in HbA1c by 0.45% and rebound in postprandial glucose.
Conclusions:
- Acarbose is an effective treatment for NIDDM.
- The drug was found to be safe and well-tolerated by patients.
- Glycemic control benefits diminished after treatment cessation.
Abstract:
An uncontrolled multicenter study of the efficacy and safety of treatment of diabetes with acarbose was conducted on 169 NIDDM patients in 12 medical centers in Israel. Acarbose was administered for 19 weeks, and the patients were followed for an additional 12 weeks. A substantial decrease in HbA1c levels from 8.5% to 7.5% (p < 0.001) and in postprandial serum glucose levels from 283.6 mg/dl to 248.5 mg/dl (p < 0.01) was seen during treatment. On follow-up, HbA1c levels increased by 0.45% and postprandial serum glucose rebounded from 256.4 mg/dl to 287.9 mg/dl. Acarbose was shown to be effective in treating NIDDM and to be safe and well-tolerated.